Cytochrome P450 polymorphisms in geriatric patients: Impact on adverse drug reactions - A pilot study

Drugs and Aging

Volumn 22, Issue 3, 2005, Pages 265-272

  Egger, Tobias ^a,d   Dormann, Harald ^a   Ahne, Gabi ^a   Pahl, Andreas ^a   Runge, Ulrich ^b   Azaz Livshits, Tanya ^c   Neubert, Antje ^a   Criegee Rieck, Manfred ^a   Gassmann, Karl G ^b   Brune, Kay ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Waldkrankenhaus St Marien ^*  (Germany)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIGESTIVE TRACT AGENT;

ADVERSE DRUG REACTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG METABOLISM; ENDOCRINE DISEASE; FEMALE; FRACTURE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; GERIATRIC DISORDER; GERMANY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OUTCOMES RESEARCH; PHARMACIST; PHARMACOEPIDEMIOLOGY; PHYSICIAN; PILOT STUDY; POLYMERASE CHAIN REACTION; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES;

EID: 20244366089     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200522030-00007     Document Type: Article

References (35)

1. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324 (6): 377-84
2. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8 (6): 289-94
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279 (15): 1200-5
4. Levy M, Azaz-Livshits T, Sadan B, et al. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur J Clin Pharmacol 1999; 54 (11): 887-92
5. Mannesse CK, Derkx FH, de Ridder MA, et al. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing 2000; 29 (1): 35-9
6. Egger T, Dormann H, Ahne G, et al. Identification of adverse drug reactions in geriatric inpatients using a computerised drug database. Drugs Aging 2003; 20 (10): 769-76
7. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161 (13): 1629-34
8. Carbonin P, Pahor M, Bernabei R, et al. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39 (11): 1093-9
9. Dormann H, Krebs S, Muth-Selbach U, et al. Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk? Aliment Pharmacol Ther 2001; 15 (2): 171-80
10. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45 (8): 945-8
11. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286 (18): 2270-9
12. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353 (9154): 717-9
13. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356 (9242): 1667-71
14. Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 2000; 10 (1): 27-34
15. Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis and management. Lancet 2000; 356 (9237): 1255-9
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30 (2): 239-45
17. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf 2000; 22 (2): 161-8
18. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions [letter]. Hosp Pharm 1992; 27 (6): 538
19. Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60 (2): 284-95
20. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7 (1): 59-64
21. Xie HG, Prasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54 (10): 1257-70
22. Flockhart DA. Cytochrome P450 drug interaction table [online]. Available from URL: http://medicine.iupui.edu/flockhart/ [Accessed 2002 Dec 2]
23. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348 (6): 538-49
24. Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. BMJ 2000; 320 (7240): 987-90
25. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348 (6): 529-37
26. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20 (8): 342-9
27. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants: the role of the CYP family of enzymes. Mutat Res 2001; 482 (1-2): 11-9
28. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41 (12): 913-58
29. Clark D, Morgan A, Hananeia L, et al. Drug metabolism genotypes and their association with adverse drug reactions in selected populations: a pilot study of methodology. Pharmacoepidemiol Drug Saf 2000; 9: 393-400
30. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001; 21 (2): 235-42
31. Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72 (4): 429-37
32. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72 (4): 438-52
33. Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants: a pilot study. Clin Pharmacol Ther 2004; 75 (5): 386-93
34. Tamminga WJ, Wemer J, Oosterhuis B, et al. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. Eur J Clin Pharmacol 2003; 59 (1): 57-64
35. Hippius M, Buchardt C, Farker K, et al. Adverse drug reaction monitoring in Jena: relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions. Exp Toxicol Pathol 2003; 54 (5-6): 417-21